Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Charles Elliott Sigal currently holds 16,000 shares of Adaptimmune Therapeutics PLC (ADAP), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Charles Elliott Sigal has been a net buyer of ADAP stock. They have purchased $338.4K and sold $0 worth of shares.
Charles Elliott Sigal's most recent insider trade was on May 27, 2026, when they sold 16,000 shares at $0.00 per share.
Charles Elliott Sigal serves as Executive at Adaptimmune Therapeutics PLC (ADAP). They have executed 18 insider transactions totaling $338.4K over their tenure at the company.
Charles Elliott Sigal holds the position of Executive at Adaptimmune Therapeutics PLC, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 10 years and currently hold a stake valued at $0.
Charles Elliott Sigal has shown a buying trading pattern, with $338.4K in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a tendency to accumulate shares.
The largest transaction by Charles Elliott Sigal was on Jan 3, 2023, when they purchased $64.0K worth of VIR shares. This transaction involved 2,500 shares at $25.60 per share.
Charles Elliott Sigal currently owns 16,000 shares of Adaptimmune Therapeutics PLC (ADAP), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Charles Elliott Sigal's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Charles Elliott Sigal has 18 Form 4 filings on record as an insider at Adaptimmune Therapeutics PLC.
Set alerts for Charles Elliott Sigal and 40,000+ other insiders.